Regimmune Corporation Company
REGiMMUNE is a clinical-stage biopharmaceutical company focused on creating innovative immunotherapies for rare diseases and cancer by leveraging underexploited biological opportunities.
Investors
Total Funding:
$55M
Investor Type:
For Profit
Technology:
Geroscience
Last Funding Type:
Post-IPO Equity
Estimated Revenue:
Less than $1M
Founded Date:
2006-03-01
Industry:
Stem Cell Exhaustion
Employee Number:
11-50
Last Funding Date:
2017-05-10
Headquarters:
Japan
Investors Number:
28